GANULAMERAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Wed Apr 02 09:22:14 GMT 2025` Edited by `admin` on `Wed Apr 02 09:22:14 GMT 2025`
Nucleic Acid Type	mRNA VACCINE
Sequence Origin	VIRAL
Sequence Type	COMPLETE
Record UNII	I74C16KK3J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BNT-162B3

Preferred Name

English

GANULAMERAN

Official Name

English

BNT162B3

Code

English

Ganulameran [WHO-DD]

Common Name

English

RNA (RECOMBINANT 5'-(1,2-((3'-O-METHYL)M7G-(5'->5')-PPP-AM))-CAPPED ALL URIDINE->N1-METHYLPSEUDOURIDINE-SUBSTITUTED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN S1S2 SECRETORY SIGNAL PEPTIDE PLUS RECEPTOR-BINDING DOMAIN FUSION PROTE

Common Name

English

ganulameran [INN]

Common Name

English

Code System Code Type Description

SMS_ID

300000027773

Created by admin on Wed Apr 02 09:22:14 GMT 2025 , Edited by admin on Wed Apr 02 09:22:14 GMT 2025

PRIMARY

CAS

2433844-55-2

Created by admin on Wed Apr 02 09:22:14 GMT 2025 , Edited by admin on Wed Apr 02 09:22:14 GMT 2025

PRIMARY

INN

11890

Created by admin on Wed Apr 02 09:22:14 GMT 2025 , Edited by admin on Wed Apr 02 09:22:14 GMT 2025

PRIMARY

FDA UNII

I74C16KK3J

Created by admin on Wed Apr 02 09:22:14 GMT 2025 , Edited by admin on Wed Apr 02 09:22:14 GMT 2025

PRIMARY

NCI_THESAURUS

C177085

Created by admin on Wed Apr 02 09:22:14 GMT 2025 , Edited by admin on Wed Apr 02 09:22:14 GMT 2025

PRIMARY

Sugar	Site Range	Site Count
D-Ribose (RNA)	1_2-1_1397	1396 / 1397
2'-O-Methyl-Ribose	1_1	1 / 1397

Linkage	Site Range	Site Count
Phosphate	1_2-1_1397	1396 / 1396

Related Record Type Details


					B6L4N5Z4GH

SARS-COV2

TARGET ORGANISM->VACCINE ANTIGEN

Amount:

Related Record Type Details


					I74C16KK3J

ACTIVE MOIETY

Comments:

Designed to produce neutralizing antibody to the SARS-CoV-2 S glycoprotein. The intention is that such antibodies would protect against SARS-CoV-2 infection and its resulting disease, COVID-19

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOSIDE_SUBSTITUTION		RESIDUE_SPECIFIC	URACIL		N1-METHYLPSEUDOURIDINE	09RAD4M6WF
NUCLEOTIDE SUBSTITUTION	[1_1]	5'-TERMINUS			UNSPECIFIED SUBSTANCE	96281b8a (not in database)